摘要
目的探讨肝细胞癌(HCC)组织中凋亡抑制蛋白Survivin与血管内皮生长因子(VEGF)表达的相关性及其临床意义。方法应用免疫组织化学方法检测50例HCC组织和20例正常肝组织中Survivin、VEGF蛋白的表达,并将检测结果与临床病理特征进行综合分析。结果(1)50例HCC组织中Survivin、VEGF蛋白的阳性表达率分别为64.0%(32/50)、68.0%(34/50),在正常肝组织中的表达率分别为0%(0/20)、10%(2/20),差异有显著性(P<0.05);(2)Survivin、VEGF蛋白表达与患者的性别、年龄、肿瘤大小、分化程度、AFP值均无相关性(P>0.05),而与临床分期及转移相关(P<0.05);(3)Survivin、VEGF蛋白表达呈正相关关系(χ2=6.69,P<0.05)。结论Survivin和VEGF蛋白在HCC中表达率较高,为肝癌的分子靶向治疗提供了新的靶点;Survivin和VEGF在HCC中的表达关系密切,测定HCC中Survivin、VEGF蛋白的表达,有助于临床判断病人预后。
Objective To assess the correlations between Survivin and vascular endothelial growth factor （VEGF） in hepatocellular carcinoma （HCC） and their clinical significance. Methods The expressions of Survivin and VEGF in 50 HCC specimens and 20 normal hepatic tissue specimens were detected by immunohistochemistry, and the results were analyzed in relation to the patients＇ clinicopathologic characteristics. Results Of the 50 HCC specimens, 32 （64.0%） were positive for Survivin expression, and 34 （68.0%） were positive for VEGF expression. Survivin expression was not detected in normal hepatic tissues, and 2 （10%） of these tissues were positive for VEGF, showing significant difference in Survivin and VEGF expressions between HCC specimens and normal hepatic tissues. Survivin and VEGF expressions were not correlated to the patients＇ gender, age, tumor＇size, degree of differentiation and alpha fetoprotein level （P〈0.05）, but related to the clinical stage and lymph node metastasis of HCC （P〈0.05）. Correlation analysis indicated a close correlation between the expressions of survivin and VEGF in the HCC specimens （χ^2=6.69, P〈0.05）. Conclusion Survivin and VEGF are over-expressed in HCC tissues, and may theoretically serve as the targets of molecular targeted drugs. Detection of the expressions of Survivin and VEGF in HCC tissues may provide assistance for prognostic evaluation of the patients.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2008年第5期761-763,共3页
Journal of Southern Medical University
基金
广东省自然科学基金(2004037050)
关键词
肝细胞癌
SURVIVIN
血管内皮生长
靶向治疗
免疫组化
hepatocellular carcinoma
Survivin
vascular endothelial growth factor
targeted therapy
immunohistochemistry
